Evidence map›Paper›PMID 40401937›Full record

ArticlemSphere2025

Ceftazidime retains

Matthew C Phillips, Bosul Lee, Sarah L Miller, Jun Yan, Kristine Goy, Marlène Maeusli, Tina Lam, Catherine Spellberg, Michael Spellberg, Rosemary She and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Clinical, microbiological, and molecular characteristics, outcomes, and risk factors for mortality of patients with Stenotrophomonas maltophilia bloodstream infection.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Matthew C PhillipsDivision of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-9329-5455
Bosul LeeDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Sarah L MillerDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Jun YanDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Kristine GoyDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Marlène MaeusliDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Tina LamDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Catherine SpellbergDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Michael SpellbergDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.
Rosemary SheDepartment of Pathology, City of Hope, Duarte, California, USA.
Brad SpellbergLos Angeles General Hospital, Los Angeles, California, USA.
Brian LunaDepartment of Molecular Microbiology and Immunology, Keck School of Medicine at USC, Los Angeles, California, USA.ORCID 0000-0001-6718-4551

Funding

INFECTIOUS DISEASE AND BASIC MICROBIOLOGICAL MECHANISMST32AI007061 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Marcia B Goldberg · 1985 to 2026
$12.1M
MAb Passive Vaccination against Acinetobacter baumanniiR01AI130060 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BRAD J SPELLBERG · 2017 to 2026
$6.7M
Characterization of Rifabutin Therapy Against Antibiotic-Resistant BacteriaR01AI139052 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LUNA, BRIAN MICHAEL · 2018 to 2021
$2.4M
Identifying Synergistic Rifabutin-Containing Combinations Against A. baumanniiR01AI179046 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Brian Michael Luna · 2024 to 2026
$1.4M
National Institute of Allergy and Infectious Diseases R01AI139052National Institute of Allergy and Infectious Diseases R01AI179046NIAID NIH HHS R01 AI130060NIAID NIH HHS R01 AI139052NIAID NIH HHS R01 AI179046NIAID NIH HHS T32 AI007061
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsCeftazidimeDrug Resistance, BacterialGram-Negative Bacterial InfectionsStenotrophomonas maltophiliaAnimalsCulture MediaDisease Models, AnimalMiceMicrobial Sensitivity TestsMothsAnti-Bacterial AgentsCeftazidimeCulture Mediaantibiotic resistancebeta-lactamasesbeta-lactamsgram-negative bacteriaStenotrophomonas

Identifiers

PMID40401937
PMCPMC12188716

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.